![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » EC Awards Marketing Authorization to GSK’s Nucala
EC Awards Marketing Authorization to GSK’s Nucala
The European Commission has awarded British drugmaker GlaxoSmithKline marketing authorization for Nucala as an add-on treatment for severe refractory eosinophilic asthma in adults.
Nucala (mepolizumab) targets interleukin-5, a protein that aids in regulating the function of eosinophils.
The FDA approved Nucala on Nov. 4 as add-on maintenance treatment for severe asthma in patients 12 and older, and with an eosinophilic phenotype. The mAb is under regulatory review in Japan and other countries.
Upcoming Events
-
21Oct